AbbVie Inc.ABBV
NYSE • Healthcare
$211.59
P/E
89.30
PEG
0.10
FCF Yield
—
Rev Growth YoY
+5.3% YoY
Gross Margin
84.0%
Health Score
7/10
D/E Ratio
-21.12
Confidence
MEDIUM
Business Snapshot
AbbVie Inc. is a large-cap biopharmaceutical company listed on the NYSE, operating primarily in the Drug Manufacturers – General industry within the Healthcare sector. The company develops and commercialises a broad portfolio of treatments across immunology, oncology, neuroscience, and aesthetics, with blockbuster franchises including Skyrizi and Rinvoq driving post-Humira growth. Based on trailing twelve-month revenue of $61.16B, AbbVie sits firmly in large-cap territory.
Financial Health
**Score: 7/10** AbbVie's financial health presents a mixed but broadly solid picture. Gross margin expanded dramatically to 84.0% from 66.4% the prior year, signalling meaningful improvement in product mix or cost structure...
Risk Assessment
- **VALUATION: P/E of 89.3x is approximately 3.6x the sector average of 25x, leaving limited margin of safety if earnings disappoint.** - **LIQUIDITY: Current ratio of 0.67x means current liabilities exceed current assets, which could create short-term funding pressure.** - **TECHNICAL TREND: Price at $211.59 sits below both the 50-day moving average ($220.93) and the 200-day moving average ($214.56), confirming a near-term downtrend.** - **DCF PREMIUM: Stock trades at a 24.2% premium to the FMP DCF fair value of $160.49, based on a high-confidence model.** - **EARNINGS QUALITY: Reported net margin of 691.0% against a net income of $4.23B on $61.16B revenue is internally inconsistent, suggesting significant non-cash, one-time, or accounting items distorting headline profitability metrics.** ---...